Topton, PA (PRWEB) March 24, 2006 -–
Joel M. Kauffman, Ph.D., will appear at a book signing event at the Maulfair Medical Center on 403 N. Main Street in Topton, Pa., on Saturday, April 29 between 1:00 p.m. and 4:00 p.m. Following the book signing, Kauffman, the author of Malignant Medical Myths: Why Medical Treatment Causes 200,000 Deaths in the USA Each Year, and How to Protect Yourself (ISBN 0741429098, 2006, Infinity Publishing) will participate in a panel discussion with Dr. Conrad Maulfair, director of the Maulfair Medical Center, to debunk the myth that chelation therapy for atherosclerosis is dangerous.
According to Dr. Maulfair, free radicals – reactive molecules that rob cells and tissues of electrons – damage LDL cholesterol, which is then more likely to adhere to the arterial wall and cause atherosclerosis. Dr. Maulfair explains that there are three components of a chelation therapy program. “First, intravenous chelation treatment removes the metastic calcium and the iron and copper that accelerate free radical damage. It also removes toxic metals, such as lead and cadmium. Second, specific mineral nutrients and antioxidants essential for healthy cell function are taken orally. Third, a comprehensive diet and exercise program supports the progress toward wellness.”
In his book, Kauffman, a professor of Chemistry at the University of the Sciences in Philadelphia, charges that the mainstream medical community’s bias against chelation therapy is unfounded:
Discouraging sick people from undergoing an effective treatment such as EDTA chelation is despicable, even more so when dangerous procedures with limited applicability and no lasting benefit such as angioplasty or bypass surgery are recommended instead. Because of the bias in mainstream medicine against chelation, most patients who accept it do so as a last resort after all conventional treatments have failed, although a majority would have been better off using chelation as a first treatment. It is estimated that by the year 2000 more than a million patients had received more than 20 million intravenous infusions of EDTA. There were no ill effects when the procedure was correctly done. About 88 percent of the patients improved.
In the introduction to the chapter on chelation therapy, Duane Graveline, M.D., M.P.H. points the finger at the economic incentives that prevent widespread acceptance of chelation therapy by the mainstream medical community:
The use of EDTA chelation to reduce the risk of atherosclerotic cardiovascular disease has resulted in a 30-year battle between proponents and opponents. The opponents are organized medicine and the pharmaceutical industry. The firm stand of organized medicine is no doubt largely derived from the alternative medicine “flavor” of chelation combined with the extraordinary economic gain from such orthodox treatment options as by-pass surgery and angioplasties, whereas the pharmaceutical is basically an economic one of “no money to be made” on such a biochemically simple and therapeutically safe procedure. Imagine that, of an estimated 20 million intravenous infusions of EDTA, there were no ill effects when properly done. This is an extraordinary safety record, far surpassing our household favorites, aspirin and Tylenol.
Dr. Maulfair finds Kauffman’s book a refreshing antidote to many of the myths surrounding health care, and looks forward to both the book signing and his participation in a panel discussion on chelation therapy. “Dr. Kauffman brings an independent view to bear on the research supporting medical care in this country. His thorough review of the scientific literature serves to debunk the myths surrounding chelation therapy and other common beliefs about medical treatment.”
# # #